Compare Stocks: APNHY, JAZZ, SGIOY, and NBIX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APNHY Aspen Pharmacare	$9.77	$9.37	$5.25 ▼ $10.05	$4.23B	0.92	1,647 shs	22 shs
JAZZ Jazz Pharmaceuticals	$210.39 -2.9%	$243.58	$128.80 ▼ $266.38	$13.66B	0.37	940,398 shs	812,595 shs
NBIX Neurocrine Biosciences	$135.13 -4.4%	$151.25	$122.14 ▼ $186.12	$13.74B	0.4	1.22 million shs	1.57 million shs
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	$8.81 +1.5%	$9.05	$7.65 ▼ $12.00	$14.99B	0.08	138,901 shs	118,892 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APNHY Aspen Pharmacare	0.00%	+2.59%	+0.51%	+8.56%	+71.25%
JAZZ Jazz Pharmaceuticals	-0.76%	-8.17%	-11.82%	-8.95%	+60.05%
NBIX Neurocrine Biosciences	-0.75%	-1.97%	-9.51%	-17.83%	+3.47%
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	-0.23%	+2.48%	-5.03%	-2.80%	+8.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APNHY Aspen Pharmacare	$9.77	$9.37	$5.25 ▼ $10.05	$4.23B	0.92	1,647 shs	22 shs
JAZZ Jazz Pharmaceuticals	$210.39 -2.9%	$243.58	$128.80 ▼ $266.38	$13.66B	0.37	940,398 shs	812,595 shs
NBIX Neurocrine Biosciences	$135.13 -4.4%	$151.25	$122.14 ▼ $186.12	$13.74B	0.4	1.22 million shs	1.57 million shs
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	$8.81 +1.5%	$9.05	$7.65 ▼ $12.00	$14.99B	0.08	138,901 shs	118,892 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APNHY Aspen Pharmacare	0.00%	+2.59%	+0.51%	+8.56%	+71.25%
JAZZ Jazz Pharmaceuticals	-0.76%	-8.17%	-11.82%	-8.95%	+60.05%
NBIX Neurocrine Biosciences	-0.75%	-1.97%	-9.51%	-17.83%	+3.47%
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	-0.23%	+2.48%	-5.03%	-2.80%	+8.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APNHY Aspen Pharmacare	0.00	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	3.00	Buy	$291.25	38.43% Upside
NBIX Neurocrine Biosciences	2.83	Moderate Buy	$201.14	48.85% Upside
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	3.33	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest APNHY, JAZZ, SGIOY, and NBIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	NBIX Neurocrine Biosciences	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Market Perform	$164.00 ➝ $150.00
10/8/2026	JAZZ Jazz Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$299.00 ➝ $296.00
10/7/2026	JAZZ Jazz Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$281.00 ➝ $286.00
10/6/2026	NBIX Neurocrine Biosciences	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$207.00
9/30/2026	JAZZ Jazz Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$325.00
9/29/2026	NBIX Neurocrine Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy (B-) ➝ Hold (C+)
9/29/2026	NBIX Neurocrine Biosciences	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$231.00 ➝ $214.00
9/24/2026	JAZZ Jazz Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$337.00
9/24/2026	JAZZ Jazz Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$337.00
9/16/2026	NBIX Neurocrine Biosciences	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
9/11/2026	JAZZ Jazz Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$315.00 ➝ $337.00

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APNHY Aspen Pharmacare	$2.07B	2.05	$0.91 per share	10.72	$10.66 per share	0.92
JAZZ Jazz Pharmaceuticals	$4.60B	2.97	$15.67 per share	13.43	$71.07 per share	2.96
NBIX Neurocrine Biosciences	$3.37B	4.07	$4.75 per share	28.42	$32.63 per share	4.14
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	$3.32B	4.52	$0.92 per share	9.61	$6.54 per share	1.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APNHY Aspen Pharmacare	$156.70M	N/A	N/A	10.51	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	-$356.15M	$14.50	14.51	9.49	0.20	20.45%	33.97%	13.02%	11/4/2026 (Estimated)
NBIX Neurocrine Biosciences	$478.60M	$6.82	19.81	14.28	0.66	20.91%	22.43%	15.64%	11/2/2026 (Estimated)
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	$1.35B	$1.00	8.81	11.15	3.12	46.67%	16.13%	12.09%	10/26/2026 (Estimated)

Latest APNHY, JAZZ, SGIOY, and NBIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	JAZZ Jazz Pharmaceuticals	$6.39	N/A	N/A	N/A	$1.20 billion	N/A
11/2/2026	Q3 2026	NBIX Neurocrine Biosciences	$1.91	N/A	N/A	N/A	$1.04 billion	N/A
10/26/2026	N/A	SGIOY Shionogi & Co., Ltd. Unsponsored ADR	$0.13	N/A	N/A	N/A	$1.11 billion	N/A
8/3/2026	Q2 2026	JAZZ Jazz Pharmaceuticals	$6.18	$5.71	-$0.47	$2.78	$1.11 billion	$1.21 billion
8/3/2026	Q1 2027	SGIOY Shionogi & Co., Ltd. Unsponsored ADR	$0.18	$0.36	+$0.18	$0.36	$970.69 million	$1.04 billion
7/31/2026	Q2 2026	NBIX Neurocrine Biosciences	$1.65	$2.85	+$1.20	$1.39	$891.16 million	$959.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APNHY Aspen Pharmacare	$0.09	0.92%	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	$0.14	1.59%	N/A	14.00%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APNHY Aspen Pharmacare	0.12	2.54	1.68
JAZZ Jazz Pharmaceuticals	0.69	1.78	1.58
NBIX Neurocrine Biosciences	N/A	1.87	1.75
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	0.01	1.14	1.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APNHY Aspen Pharmacare	N/A
JAZZ Jazz Pharmaceuticals	89.14%
NBIX Neurocrine Biosciences	92.59%
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	1.92%

Insider Ownership

Company	Insider Ownership
APNHY Aspen Pharmacare	N/A
JAZZ Jazz Pharmaceuticals	4.10%
NBIX Neurocrine Biosciences	4.60%
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APNHY Aspen Pharmacare	9,557	432.92 million	N/A	Not Optionable
JAZZ Jazz Pharmaceuticals	2,890	64.92 million	62.25 million	Optionable
NBIX Neurocrine Biosciences	2,000	101.65 million	96.97 million	Optionable
SGIOY Shionogi & Co., Ltd. Unsponsored ADR	6,223	1.70 billion	N/A	Not Optionable

APNHY, JAZZ, SGIOY, and NBIX Headlines

Recent News About These Companies

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Shorted: Short Interest Down 97.4% in September

October 11 at 1:00 PM | americanbankingnews.com

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Large Drop in Short Interest

October 9, 2026 | marketbeat.com

Contrasting Orion OYJ (OTCMKTS:ORINY) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)

October 8, 2026 | americanbankingnews.com

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) versus Tilray Brands (NASDAQ:TLRY) Head to Head Analysis

October 8, 2026 | americanbankingnews.com

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up - Here's What Happened

October 6, 2026 | marketbeat.com

Financial Survey: Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) & Lexaria Bioscience (NASDAQ:LEXX)

October 6, 2026 | americanbankingnews.com

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down - Here's What Happened

October 1, 2026 | marketbeat.com

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Short Interest Update

September 24, 2026 | marketbeat.com

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down - Time to Sell?

September 24, 2026 | marketbeat.com

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up - Here's Why

September 18, 2026 | marketbeat.com

SGIOY vs. SDZNY: Which Stock Is the Better Value Option?

March 26, 2026 | zacks.com

SGIOY vs. SDZNY: Which Stock Should Value Investors Buy Now?

March 10, 2026 | zacks.com

SGIOY or SDZNY: Which Is the Better Value Stock Right Now?

February 19, 2026 | zacks.com

All You Need to Know About Shionogi & Co. (SGIOY) Rating Upgrade to Buy

February 4, 2026 | msn.com

SGIOY vs. ZTS: Which Stock Is the Better Value Option?

February 3, 2026 | zacks.com

Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits

January 20, 2026 | reuters.com

Yomiuri: Nobel Prize Winner, Shionogi Jointly Developing New Cancer Drug

November 15, 2025 | marketwatch.com

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure

September 3, 2025 | ncnewsonline.comN

Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs

August 19, 2025 | bloomberg.com

SGIOY | Shionogi & Co. Ltd. ADR Annual Balance Sheet - WSJ

July 15, 2025 | wsj.com

SGIOY or ZTS: Which Is the Better Value Stock Right Now?

July 7, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APNHY, JAZZ, SGIOY, and NBIX Company Descriptions

Aspen Pharmacare OTCMKTS:APNHY

$9.77 0.00 (0.00%)

As of 10/12/2026

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.

Jazz Pharmaceuticals NASDAQ:JAZZ

$210.39 -6.36 (-2.93%)

Closing price 04:00 PM Eastern

Extended Trading

$211.48 +1.09 (+0.52%)

As of 07:03 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Neurocrine Biosciences NASDAQ:NBIX

$135.13 -6.24 (-4.41%)

Closing price 04:00 PM Eastern

Extended Trading

$135.32 +0.19 (+0.14%)

As of 06:54 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Shionogi & Co., Ltd. Unsponsored ADR OTCMKTS:SGIOY

$8.81 +0.13 (+1.50%)

As of 03:55 PM Eastern

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APNHY, JAZZ, SGIOY, and NBIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APNHY, JAZZ, SGIOY, and NBIX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APNHY, JAZZ, SGIOY, and NBIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APNHY, JAZZ, SGIOY, and NBIX Company Descriptions

Aspen Pharmacare OTCMKTS:APNHY

Jazz Pharmaceuticals NASDAQ:JAZZ

Neurocrine Biosciences NASDAQ:NBIX

Shionogi & Co., Ltd. Unsponsored ADR OTCMKTS:SGIOY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APNHY, JAZZ, SGIOY, and NBIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APNHY, JAZZ, SGIOY, and NBIX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APNHY, JAZZ, SGIOY, and NBIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APNHY, JAZZ, SGIOY, and NBIX Company Descriptions

Aspen Pharmacare OTCMKTS:APNHY

Jazz Pharmaceuticals NASDAQ:JAZZ

Neurocrine Biosciences NASDAQ:NBIX

Shionogi & Co., Ltd. Unsponsored ADR OTCMKTS:SGIOY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools